<DOC>
	<DOCNO>NCT02281786</DOCNO>
	<brief_summary>This single center , randomize , investigator/subject blind , single ascend dose , placebo-controlled , parallel study evaluate safety , tolerability pharmacokinetics RO6926496 healthy male participant . The dose escalation adaptive nature . It plan enroll 48 subject 6 cohort . The anticipated total duration study 16 week .</brief_summary>
	<brief_title>A Study RO6926496 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male participant , 18 45 year age ; healthy status define absence evidence active chronic disease follow detailed medical surgical history A body mass index 18 30 kg/m2 Male subject partner childbearing potential must agree use 2 method contraception , one must barrier method duration study Positive hepatitis B , hepatitis C , HIV infection History clinically significant disease disorder Clinically significant abnormality laboratory test result Participation investigational drug device study within 90 day prior screen Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk subject study History presence clinically significant ECG abnormalities Smokers smoke 10 cigarette daily equivalent unable unwilling smoke inclinic period Any clinically relevant history hypersensitivity allergic reaction Any familial history early onset Alzheimer 's disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>